EP3113760A4 - Anwendung von mechanischer kraft durch ferngesteuerte rotation - Google Patents

Anwendung von mechanischer kraft durch ferngesteuerte rotation Download PDF

Info

Publication number
EP3113760A4
EP3113760A4 EP15759285.8A EP15759285A EP3113760A4 EP 3113760 A4 EP3113760 A4 EP 3113760A4 EP 15759285 A EP15759285 A EP 15759285A EP 3113760 A4 EP3113760 A4 EP 3113760A4
Authority
EP
European Patent Office
Prior art keywords
remote
mechanical force
applying mechanical
controlled rotation
rotation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP15759285.8A
Other languages
English (en)
French (fr)
Other versions
EP3113760A1 (de
Inventor
Erik RENSTROM
Ernst Stetter
Moritz F. KIRCHER
Martin Koch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of EP3113760A1 publication Critical patent/EP3113760A1/de
Publication of EP3113760A4 publication Critical patent/EP3113760A4/de
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00Nanotechnology for materials or surface science, e.g. nanocomposites
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP15759285.8A 2014-03-04 2015-03-04 Anwendung von mechanischer kraft durch ferngesteuerte rotation Ceased EP3113760A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461947830P 2014-03-04 2014-03-04
PCT/US2015/018746 WO2015134620A1 (en) 2014-03-04 2015-03-04 Applying mechanical force by remote-controlled rotation

Publications (2)

Publication Number Publication Date
EP3113760A1 EP3113760A1 (de) 2017-01-11
EP3113760A4 true EP3113760A4 (de) 2017-08-23

Family

ID=54055841

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15759285.8A Ceased EP3113760A4 (de) 2014-03-04 2015-03-04 Anwendung von mechanischer kraft durch ferngesteuerte rotation

Country Status (3)

Country Link
EP (1) EP3113760A4 (de)
CA (1) CA2941635A1 (de)
WO (1) WO2015134620A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2900686A1 (en) 2013-02-20 2014-08-28 Sloan-Kettering Institute For Cancer Research Wide field raman imaging apparatus and associated methods
US10912947B2 (en) 2014-03-04 2021-02-09 Memorial Sloan Kettering Cancer Center Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
US10688202B2 (en) 2014-07-28 2020-06-23 Memorial Sloan-Kettering Cancer Center Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes
WO2016176509A1 (en) 2015-04-28 2016-11-03 University Of Washington Ferromagnetic shaped memory alloy nano-actuator and method of use
CA2990223A1 (en) 2015-07-01 2017-01-05 Memorial Sloan Kettering Cancer Center Anisotropic particles, methods and uses thereof
GB2566995B (en) 2017-09-29 2023-01-18 Cotton Mouton Diagnostics Ltd A method of detection
CN114901261A (zh) * 2019-04-02 2022-08-12 淅川海灵生物科技有限公司 细胞外液中激活的原子粒子的动态团簇

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005030986A1 (de) * 2005-07-02 2007-01-11 Ernst Stetter Rotierende magnetische Nanopartikel
EP2671613A2 (de) * 2011-02-01 2013-12-11 Korea University Research And Business Foundation Rotierender nanodraht und verfahren zur einleitung einer zellnekrose damit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187082A1 (en) * 2001-06-06 2002-12-12 Chang-Yu Wu Photocatalyst coated magnetic composite particle
WO2005065282A2 (en) * 2003-12-31 2005-07-21 The Regents Of The University Of California Remote magnetically induced treatment of cancer
WO2009040811A2 (en) * 2007-09-24 2009-04-02 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
WO2009047587A1 (en) * 2007-10-12 2009-04-16 Ecole Polytechnique Federale De Lausanne (Epfl) Magnetic, paramagnetic and/or superparamagnetic nanoparticles
WO2012027747A2 (en) * 2010-08-27 2012-03-01 The Regents Of The University Of Michigan Asynchronous magnetic bead rotation sensing systems and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005030986A1 (de) * 2005-07-02 2007-01-11 Ernst Stetter Rotierende magnetische Nanopartikel
EP2671613A2 (de) * 2011-02-01 2013-12-11 Korea University Research And Business Foundation Rotierender nanodraht und verfahren zur einleitung einer zellnekrose damit

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZHANG ENMING ET AL: "Alternating Magnetic Fields Trigger Apoptosis by Destruction of Lysosomes with LAMP1-Targeted Nanoparticles", BIOPHYSICAL JOURNAL, vol. 100, no. 3, Suppl. 1, February 2011 (2011-02-01), & 55TH ANNUAL MEETING OF THE BIOPHYSICAL-SOCIETY; BALTIMORE, MD, USA; MARCH 05 -09, 2011, pages 472, XP009194837, ISSN: 1542-0086 *
ZHANG ENMING ET AL: "Dynamic magnetic fields remote-control apoptosis via nanoparticle rotation.", ACS NANO 22 APR 2014, vol. 8, no. 4, 5 March 2014 (2014-03-05), pages 3192 - 3201, XP002771688, ISSN: 1936-086X *

Also Published As

Publication number Publication date
CA2941635A1 (en) 2015-09-11
EP3113760A1 (de) 2017-01-11
WO2015134620A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
EP3240164A4 (de) Aktuator
EP3221535A4 (de) Elektromechanischer schlosssatz
EP3197560A4 (de) Kapselaggregate
EP3111304A4 (de) Anwendungsstart
EP3175693A4 (de) Fernsteuerungsvorrichtung
EP3197026A4 (de) Drehstellantrieb
EP3180708A4 (de) Entfernte anwendungsserver
EP3125791A4 (de) Verstärkte vorrichtung mit hohem drehmoment
EP3135905A4 (de) Rotor
EP3240755A4 (de) Mems-antrieb
EP3160559A4 (de) Mikrobefeuchter
EP3107191A4 (de) Rotor
EP3184498A4 (de) Abstandshalter
EP3120250A4 (de) Festlaufwerkbetriebsverfahren
EP3214737A4 (de) Antriebsvorrichtung
EP3113760A4 (de) Anwendung von mechanischer kraft durch ferngesteuerte rotation
EP3219589A4 (de) Strukturelement
EP3181181A4 (de) Mikronadel mit retinol oder retinolderivat
EP3159538A4 (de) Antriebsvorrichtung
EP3153461A4 (de) Mems-vorrichtung
EP3137719A4 (de) Stangenrotationsvorrichtung
EP3124817A4 (de) Drehungsübertragungsvorrichtung
EP3168499A4 (de) Endantriebsvorrichtung
EP3267056A4 (de) Rotationsmechanismus
EP3158159A4 (de) Mechanischer kraftgenerator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RENSTROM, ERIK

Inventor name: STETTER, ERNST

Inventor name: KIRCHER, MORITZ, F.

Inventor name: KOCH, MARTIN

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61N 2/06 20060101ALI20170713BHEP

Ipc: A61K 9/14 20060101AFI20170713BHEP

Ipc: B82Y 30/00 20110101ALI20170713BHEP

Ipc: C07K 16/30 20060101ALI20170713BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20170721

17Q First examination report despatched

Effective date: 20180627

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20200223